The Fasting Study - Unraveling the Mechanistic Effects of Prolonged Fasting in Humans.
1 other identifier
interventional
24
1 country
1
Brief Summary
Elevated levels of plasma triglycerides are increasingly recognized as an important causal risk factor for cardiovascular disease and associated pathologies. Lowering plasma triglycerides may therefore be a therapeutic target to lower cardiovascular disease risk. With this study the investigators want to examine the effects of fasting on adipose tissue metabolism in humans.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2018
Shorter than P25 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 9, 2018
CompletedStudy Start
First participant enrolled
November 12, 2018
CompletedFirst Posted
Study publicly available on registry
November 29, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 22, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
January 22, 2019
CompletedApril 24, 2019
April 1, 2019
2 months
November 9, 2018
April 23, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (4)
Change in ANGPTL4 protein and gene expression in adipose tissue
Using Western blotting, the change in ANGPTL4 protein expression in adipose tissue will be measured from fed to a prolonged fasted state. The change in ANGPTL4 gene expression in adipose tissue will be measured from fed to a prolonged fasted state using whole genome affymetrix microarrays and targeted quantitative real time PCR.
there are 24 hours between the measurement in de fed and the fasted state
Change in LPL expression, both gene and protein, and LPL activity in adipose tissue
Using Western blotting, the change in LPL protein expression in adipose tissue will be measured from fed to a prolonged fasted state. The change in LPL gene expression in adipose tissue will be measured from fed to a prolonged fasted state using whole genome affymetrix microarrays and targeted quantitative real time PCR. The change in LPL activity in subcutaneous adipose tissue will be measured from fed to a prolonged fasted state, using a lipoprotein lipase assay.
There are 24 hours between the measurement in the fed and the fasted state
Change in ANGPTL4 expression in plasma
Using ELISA, the change in ANGPTL4 expression in plasma will be measured from fed to a prolonged fasted state.
There are 24 hours between the measurement in the fed and the fasted state
Change in ANGPTL4 and LPL gene expression in PBMCs
The change in ANGPTL4 and LPL gene expression in PBMCs from fed to a prolonged fasted state will be measured using whole genome affymetrix microarrays and targeted quantitative real time PCR.
There are 24 hours between the measurement in the fed and the fasted state
Secondary Outcomes (4)
Change in whole genome expression
There are 24 hours between the measurement in the fed and the fasted state
Post-transcriptional changes
There are 24 hours between the measurement in the fed and the fasted state
Changes in metabolite profiles
There are 24 hours between the measurement in the fed and the fasted state
Changes in protein profiles
There are 24 hours between the measurement in the fed and the fasted state
Other Outcomes (1)
BMI
At baseline
Study Arms (1)
Intervention arm
EXPERIMENTALFasting for 26-hours.
Interventions
All research subjects will have to fast for 26 hours in total. All research subjects start with a standardized meal. Two hours after the standardized meal the samples in the fed state will be taken. Research participants are not allowed to eat anything after the consumption of the standardized meal until the second measurements on day 2, 26-hours later. There are 24 hours between the two measurement points.
Eligibility Criteria
You may qualify if:
- Apparently healthy man or woman
- Age 40-70y at the time of recruitment
- BMI of 22-30 kg/m2
- Willing to fast for 26 hours
- Willing to give blood samples
- Willing to give adipose tissue biopsies
- Willing to consume the standardized meal on test day 1
- Signed informed consent
- Having a general practitioner
You may not qualify if:
- Alcohol on average: more than 2 consumptions/day or more than 14 consumptions/week
- Tobacco smoker
- Usage of drugs
- Following a diet within one month of starting the study (for example a ketogenic diet)
- Allergic to one or more components of the standardized meal
- Donated or intend to donate blood from 2 months before the study until the end of the study
- Unstable body weight (weight gain or loss \>5 kg in the past three months)
- Diagnosed with any long-term medical condition that can interfere with the study outcome (i.e. cardiovascular disease, diabetes mellitus type 1 or 2, liver, pulmonary, or renal disease)
- Use of prescribed medication
- Use of supplements or over the counter medication (OTC) known to interfere with glucose or lipid homeostasis in the week before the start of the study, and during the study
- Being pregnant or lactating
- Participation in another biomedical study (other than the EetMeetWeet study) during this study
- Members of the research team, or first degree family members of the research team
- Working, or doing an internship at the division "Human Nutrition and Health" - Wageningen University
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Wageningen University, Division of Human Nutrition
Wageningen, Gelderland, 6700 EV, Netherlands
Related Publications (1)
Ruppert PMM, Michielsen CCJR, Hazebroek EJ, Pirayesh A, Olivecrona G, Afman LA, Kersten S. Fasting induces ANGPTL4 and reduces LPL activity in human adipose tissue. Mol Metab. 2020 Oct;40:101033. doi: 10.1016/j.molmet.2020.101033. Epub 2020 Jun 3.
PMID: 32504883DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lydia Afman, PhD
Wageningen University
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
November 9, 2018
First Posted
November 29, 2018
Study Start
November 12, 2018
Primary Completion
January 22, 2019
Study Completion
January 22, 2019
Last Updated
April 24, 2019
Record last verified: 2019-04